The FDA 503A Bulks List is the federal list of certain bulk drug substances that may be used in traditional patient-specific compounding when there is no applicable USP or NF drug-substance monograph and the substance is not a component of an FDA-approved drug
GHK-Cu downregulates inflammatory cytokines, reduces the activity of pro-inflammatory signaling cascades, and modulates p38 MAPK in a way that reduces inflammatory response without suppressing the growth factor signaling needed for tissue repair
Aesthetic indications include melasma, post-inflammatory hyperpigmentation, uneven skin tone, and general luminosity and anti-aging protocols
Download the app to get research-backed guidance on peptide therapy, compounding access, and regulatory developments as they happen.
The pharmacies also are not required to follow the same production safety standards as traditional drug manufacturers or to share with the FDA any problems reported by patients